Acquired myasthenia gravis in dogs - Part II

Compendium on Continuing Education for the Practicing Veterinarian

Volumn 20, Issue 1, 1998, Pages 47-57

  Dewey, C W ^a,b,c,d  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c AMER COLL OF VET INT MEDICINE   (United States)

^d Amer College of Veterinary Surgeons   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANIS FAMILIARIS;

EID: 0038415441     PISSN: 01931903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Watson RF, Lisak RP: Myasthenia gravis: An overview, in Lisak RP (ed): Handbook of Myasthenia Gravis and Myasthenic Syndromes. New York, Marcel Dekker, 1994, pp 1-19.
2. Sanders DB, Howard JF: Disorders of neuromuscular transmission, in Bradley WG, Daroff RB, Fenichel GM, Marsden CD (eds): Neurology in Clinical Practice: The Neurological Disorders. Boston, Butterworth-Heinemann, 1991, pp 1819-1842.
3. Hohlfeld R, Toyka KV: Therapies, in DeBaets MH, Oosterhuis HJG (eds): Myasthenia Gravis. London, CRC Press, 1993, pp 236-261.
4. Drachman DB: Myasthenia gravis. N Engl J Med 330: 1797-1810, 1994.
5. Lindstrom J, Shelton D, Fujii Y: Myasthenia gravis. Adv Immunol 42:233-284, 1988.
6. Swash M, Schwartz M: Myasthenia gravis and other myasthenic syndromes, in Swash M, Schwartz M (eds): Neuromuscular Diseases: A Practical Approach to Diagnosis and Management, ed 2. New York, Springer-Verlag, 1988, pp 229-250.
7. Lisak RP, Barchi RL: Myasthenia gravis, in Walton JN (ed): Major Problems in Neurology. Philadelphia, WB Saunders Co, 1982, pp 5-36.
8. Shelton GD: Canine myasthenia gravis, in Kirk RW, Bonagura JD (eds): Current Veterinary Therapy. XI. Philadelphia, WB Saunders Co, 1992, pp 1039-1042.
9. Dewey CW, Shelton GD, Bailey CS, et al: Neuromuscular dysfunction in five dogs with acquired myasthenia gravis and presumptive hypothyroidism. Prog Vet Neurol 6(4):117-123, 1995.
10. Hackett TB, Van Pelt DR, Willard MD, et al: Third-degree atrioventricular block and acquired myasthenia gravis in four dogs. JAVMA 206(8):1173-1176, 1995.
11. Levin KH, Richman DP: Myasthenia gravis, in Adachi M, Sher JH (eds): Current Trends in Neurosciences: Neuromuscular Disease. New York, Igaki-Shoin, 1990, pp 296-317.
12. Genkins G, Kornfeld P, Papatestas AE, et al: Clinical experience in more than 2000 patients with myasthenia gravis. Ann NY Acad Sci 505:500-513, 1987.
13. Shelton GD: Disorders of neuromuscular transmission. Semin Vet Med Surg 4:126-132, 1989.
14. Shelton GD: Megaesophagus secondary to acquired myasthenia gravis, in Kirk RW, Bonagura JD (eds): Current Veterinary Therapy. XI. Philadelphia, WB Saunders Co, 1992, pp 580-583.
15. Van Heerden J, Van Schouwenburg SJ: The use of corticosteroids in a dog with myasthenia gravis. J S Afr Vet Assoc 54(2):135-137, 1983.
16. Maddison JE, Waelchli-Suter CM, Johnson RP, et al: Clinical remission after corticosteroid therapy of acquired myasthenia in three dogs. JAVMA 184(7):845-848, 1984.
17. Bartges JW, Klausner JS, Bostwick EF, et al: Clinical remission following plasmapheresis and corticosteroid treatment in a dog with acquired myasthenia gravis. JAVMA 196(8):1276-1278, 1990.
18. Dewey CW, Bailey CS, Shelton GD, et al: Clinical forms of acquired myasthenia gravis in dogs: 25 cases (1988-1995). J Vet Intern Med 11:50-57, 1997.
19. Klebanow ER: Thymomas and acquired myasthenia gravis in the dog: A case report and review of 13 additional cases. JAAHA 28:63-69, 1992.
20. Atwater SW, Powers BE, Park RD, et al: Thymoma in dogs: 23 cases (1980-1991). JAVMA 205(7):1007-1013, 1994.
21. Chantal Lainesse MF, Taylor SM, Myers SL, et al: Focal myasthenia gravis as a paraneoplastic syndrome of canine thymoma: Improvement following thymectomy. JAAHA 32: 111-117, 1996.
22. Rusbridge C, White RN, Elwood CM, et al: Treatment of acquired myasthenia gravis associated with thymoma in two dogs. J Small Anim Pract 36:376-380, 1996.
23. Shelton GD, Willard MD, Cardinet GH, et al: Acquired myasthenia gravis: Selective involvement of esophageal, pharyngeal, and facial muscles. J Vet Intern Med 4:281-284, 1990.
24. Wheeler SJ: Disorders of the neuromuscular junction. Prog Vet Neurol 2(2):129-135, 1990.
25. Plumb DC: Veterinary Drug Handbook, ed 2. White Bear Lake, MN, PharmaVet Publishing, 1995.
26. Sergott RC: Ocular myasthenia, in Lisak RP (ed): Handbook of Myasthenia Gravis and Myasthenic Syndromes. New York, Marcel Dekker, 1994, pp 21-31.
27. Johns TR: Long-term corticosteroid treatment of myasthenia gravis. Ann NY Acad Sci 505:568-583, 1987.
28. Miller RG, Milner-Brown HS, Mirka A: Prednisone-induced worsening of neuromuscular function in myasthenia gravis. Neurology 36:729-732, 1986.
29. Matell G: Immunosuppressive drugs: Azathioprine in the treatment of myasthenia gravis. Ann NY Acad Sci 505:588-594, 1987.
30. Miller E: Immunosuppressive therapy in the treatment of immune-mediated disease. J Vet Intern Med 6:206-213, 1992.
31. Stewart AF, Feldman BF: Immune-mediated hemolytic anemia. Part II. Clinical entity, diagnosis, and treatment theory. Compend Contin Educ Pract Vet 15(11):1479-1491, 1993.
32. Mackin A: Canine immune-mediated thrombocytopenia - Part II. Compend Contin Educ Pract Vet 17(4):515-535, 1995.
33. Taboada J, Hoskins JD, Morgan RV: Respiratory emergencies, in Emergency Medicine in Small Animal Practice. Trenton, NJ, Veterinary Learning System, 1997, pp 227-247.
34. Drachman DB, Adams RN, McIntosh K, et al: Treatment of experimental myasthenia gravis with cyclosporine A. Clin Immunol Immunopathol 34:174-178, 1985.
35. Tindall RSA, Phillips JT, Rollins JA, et al: A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci 681:539-551, 1993.
36. Vaden SL: Cyclosporine, in Bonagura JD (ed): Kirk's Current Veterinary Therapy. XII. Philadelphia, WB Saunders Co, 1995, pp 73-77.
37. Oates JA, Wood AJJ: Manipulating the immune system with immune globulin. N Engl J Med 326(2):107-116, 1992.
38. Arsura E: Experience with intravenous immunoglobulin in myasthenia gravis. Clin Immunol Immunopathol 53:S170-S179, 1989.
39. Van Der Meché FGA, Van Doorn PA: The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders. Muscle Nerve 20:136-147, 1997.
40. Keesey J, Buffkin D, Kebo D, et al: Plasma exchange alone as therapy for myasthenia gravis. Ann NY Acad Sci 377:729-743, 1981.
41. Pinching AJ, Peters DK, Newsom-Davis J: Remission of myasthenia gravis following plasma exchange. Lancet 2: 1373-1376, 1976.
42. Buckingham JM, Howard FM, Bernatz PE, et al: The value of thymectomy in myasthenia gravis: A computer-assisted matched study. Ann Surg 184(4):453-458, 1976.
43. Hebra AE, Reed CE, Heldmann M, et al: Myasthenia gravis: A review with emphasis on the potential role of thymectomy. J S C Med Assoc:392-396, 1990.
44. Kuroda Y, Oda K, Neshige R, et al: Exacerbation of myasthenia gravis after removal of a thymoma having a membrane phenotype of suppressor T cells. Ann Neurol 15:400-402, 1984.
45. Walker AN, Mills SE, Fechner RE: Thymomas and thymic carcinomas. Semin Diag Pathol 7(4):250-265, 1990.
46. Batra P, Herrman C, Mulder D: Mediastinal imaging in myasthenia gravis: Correlation of chest radiography, CT, MR, and surgical findings. Am J Roentgenol 148:515-519, 1987.
47. Hitt ME, Shaw DP, Hogan PM, et al: Radiation treatment for thymoma in a dog. JAVMA 190(9):1187-1190, 1987.
48. Mears EA, Jenkins CC: Canine and feline megaesophagus. Compend Contin Educ Pract Vet 19(3):313-326, 1997.
49. Guilford WG: Megaesophagus in the dog and cat. Semin Vet Med Surg 5(1):37-45, 1990.
50. Twedt DC: Diseases of the esophagus, in Ettinger SJ, Feldman EC (eds): Textbook of Veterinary Internal Medicine, ed 4. Philadelphia, WB Saunders Co, 1995, pp 1124-1142.
51. Strombeck DR, Guilford WG: Pharynx and esophagus - Normal structure and function, in Strombeck DR, Guilford WG (eds): Small Animal Gastroenterology, ed 2. Davis, CA, Stonegate Publishing Co, 1990, pp 129-139.
52. Seim HB, Willard M: Postoperative care of the surgical patient, in Fossum TW (ed): Small Animal Surgery. St Louis, Mosby-Year Book, 1997, pp 64-85.
53. Hall JA, Washabau RJ: Gastrointestinal prokinetic therapy: Dopaminergic antagonistic drugs. Compend Contin Educ Pract Vet 19(2):214-221, 1997.
54. Washabau RJ, Hall JA: Gastrointestinal prokinetic therapy: Serotonergic drugs. Compend Contin Educ Pract Vet 19(4):473-480, 1997.
55. Washabau RJ, Hall JA: Cisapride. JAVMA 207(10): 1285-1288, 1995.
56. Oosterhuis HJG: Clinical aspects, in DeBaets MH, Oosterhuis HJG (eds): Myasthenia Gravis. London, CRC Press, 1993, pp 13-42.
57. Krotje LJ, Fix AS, Potthoff AD: Acquired myasthenia gravis and cholangiocellular carcinoma in a dog. JAVMA 197(4): 488-490, 1990.
58. Moore AS, Madewell BR, Cardinet GH, et al: Osteogenic sarcoma and myasthenia gravis in a dog. JAVMA 197(2): 226-227, 1990.
59. Morgenthaler TI, Brown LR, Colby TV, et al: Thymoma. Mayo Clin Proc 68:1110-1123, 1993.
60. Sherer Y, Bar-Dayan Y, Schoenfeld Y: Thymoma, thymic hyperplasia, thymectomy, and autoimmune diseases. Int J Oncol 10(5):939-943, 1997.
61. Aronsohn M: Canine thymoma. Vet Clin North Am Small Anim Pract 15(4):755-767, 1985.
62. Bellah JR, Stiff ME, Russell RG: Thymoma in the dog: Two case reports and review of 20 additional cases. JAVMA 183(3):306-311, 1983.
63. Aronsohn MG, Schunk KL, Carpenter JL, et al: Clinical and pathologic features of thymoma in 15 dogs. JAVMA 184(11): 1355-1361, 1984.
64. Cikes N, Momoi MY, Williams CL, et al: Striational autoantibodies: Quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of D-penicillamine or allogeneic bone marrow. Mayo Clin Proc 63:474-481, 1988.
65. Steiner I, Brenner T, Soffer D, et al: Involvement of sites other than the neuromuscular junction in myasthenia gravis, in Lisak RP (ed): Handbook of Myasthenia Gravis and Myasthenic Syndromes. New York, Marcel Dekker, 1994, pp 277-294.
66. Howard JF: Adverse drug effects on neuromuscular transmission. Semin Neurol 10(1):89-102, 1990.
67. Wittbrodt ET: Drugs and myasthenia gravis: An update. Arch Intern Med 157:399-408, 1997.
68. Drachman DB, McIntosh KR, Reim J, et al: Strategies for treatment of myasthenia gravis. Ann NY Acad Sci 681:515-528, 1993.
69. Reim J, McIntosh K, Martin S, et al: Specific immunotherapeutic strategy for myasthenia gravis: Targeted antigen-presenting cells. J Neuroimmunol 41:61-70, 1992.
70. Wang ZY, Qiao J, Link H: Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J Neuroimmunol 44:209-214, 1993.
71. Thompson HS, Staines NA: Could specific oral tolerance be a therapy for autoimmune disease? Immunol Today 11:396-399, 1990.